Your browser doesn't support javascript.
loading
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
Lewis, Alexander C; Pope, Victoria S; Tea, Melinda N; Li, Manjun; Nwosu, Gus O; Nguyen, Thao M; Wallington-Beddoe, Craig T; Moretti, Paul A B; Anderson, Dovile; Creek, Darren J; Costabile, Maurizio; Ali, Saira R; Thompson-Peach, Chloe A L; Dredge, B Kate; Bert, Andrew G; Goodall, Gregory J; Ekert, Paul G; Brown, Anna L; D'Andrea, Richard; Robinson, Nirmal; Pitman, Melissa R; Thomas, Daniel; Ross, David M; Gliddon, Briony L; Powell, Jason A; Pitson, Stuart M.
Afiliação
  • Lewis AC; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Pope VS; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Tea MN; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Li M; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Nwosu GO; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Nguyen TM; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Wallington-Beddoe CT; Faculty of Health Sciences, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • Moretti PAB; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Anderson D; Faculty of Health Sciences, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • Creek DJ; College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.
  • Costabile M; Flinders Medical Centre, Bedford Park, SA, Australia.
  • Ali SR; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Thompson-Peach CAL; Drug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
  • Dredge BK; Drug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
  • Bert AG; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Goodall GJ; Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Ekert PG; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Brown AL; Faculty of Health Sciences, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • D'Andrea R; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
  • Robinson N; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Pitman MR; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Thomas D; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Ross DM; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
  • Gliddon BL; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Powell JA; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC, Australia.
  • Pitson SM; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
Blood ; 139(26): 3737-3751, 2022 06 30.
Article em En | MEDLINE | ID: mdl-35443029
ABSTRACT
Inducing cell death by the sphingolipid ceramide is a potential anticancer strategy, but the underlying mechanisms remain poorly defined. In this study, triggering an accumulation of ceramide in acute myeloid leukemia (AML) cells by inhibition of sphingosine kinase induced an apoptotic integrated stress response (ISR) through protein kinase R-mediated activation of the master transcription factor ATF4. This effect led to transcription of the BH3-only protein Noxa and degradation of the prosurvival Mcl-1 protein on which AML cells are highly dependent for survival. Targeting this novel ISR pathway, in combination with the Bcl-2 inhibitor venetoclax, synergistically killed primary AML blasts, including those with venetoclax-resistant mutations, as well as immunophenotypic leukemic stem cells, and reduced leukemic engraftment in patient-derived AML xenografts. Collectively, these findings provide mechanistic insight into the anticancer effects of ceramide and preclinical evidence for new approaches to augment Bcl-2 inhibition in the therapy of AML and other cancers with high Mcl-1 dependency.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article